Member Info for OAMOT

Wyn are you suggesting a big time lag / delay from screening to start? Screening is checking a patient who wants to join the trial is medically eligible. How can that take 6 months? That must occur very quickly as patients are ill (terminally without treatment).

With DX sale due why will they raise in the next 6 months?

Curious how you see what you are seeing this so differently.

If DX made enough to pay HCI we should bring AS back as he’s a genius!! Thats 12m in payments annually so on 10-15 times profit for a broad valuation basis DX is a 120-180m business. Most people expect a haircut on DX - its way off paying HCI. Realistically it might make one quarters payment each year. It needs selling.

And in 36 out of 40 patients the doc cleaved had no significant impact on the tumour.

That’s not true though is it? Many more have had stable disease which is a significant impact. And some tumour types will not be dox treatable. And others will have had so many treatments they are no longer sensitive.

You appear to have moved argument though mid thread to try and find something negative that’ll stick.

I haven’t read the whole thread but we’ve had confirmation that vesicant (cancer killing) quantities of dox are in the tumours. And 1/100th of that amount in the blood. That feels like it answers the question. Enough cleaves to kill cancer. Not enough escapes for widespread off target damage.

I thought they could forward sell until the price setting period for their next issue? Could be wrong.

I am on TG and I have to say I can’t remember Albert saying to sell. Feels like it would have stuck in my mind. I know quite a number of other TG members and none have sold.

He has other NED roles including chair elsewhere already. Not sure it impacts his Avacta role - I don’t expect it will be a huge time commitment to any of the NED roles. Just shows he is a good guy and in demand as a NED.

I think each participant completes the trial in 24 days. 2 doses 3 weeks apart with 3 days observations after dose 2. So current cohort could be about to end. Even if there is 2 weeks after first patient before anyone else joins the end could be close now> especially is recruitment is fast now with doctors wanting patients on the trial as it is having an impact

I’ve read some nonsense on here in the past 3 years but this latest argument that confirmed effectiveness is probably just placebo really must get the award for worst FUD ever.

Every participant is in a horrible position having exhausted all care options. Several are still on the trial enjoying progression free survival. A great thing for them and also a key efficacy indicator for a cancer treatment.

The idea this is just a coincidence is pretty bizarre.

Let’s look at the options:

Option 1 the power of the mind has stopped a late stage cancer growing (coincidentally at the same time an established treatment is being administered).

Option 2 The established cancer treatment being administered is treating the cancer.

On balance I am thinking option 2 is most likely?

I know someone who will be there so I will get it asked!

@KONG

I have wondered for a while if the doses in 1b will be delivered more frequently. AS references more frequent doses again today. Everything could be on a shorter timeframe than we think.

This may well have been said already as so many posts on here today. But patients from earlier cohorts (plural) still receiving AVA6000. So at I least someone from C3 which ended last September - if not an even earlier cohort. That means people are being dosed for around a year at more than the max dose of dox which can only normally be taken for 15 weeks. This is incredible. The reaction today is muted to say the least!!

As progression free survival is a prime efficacy measure this news is enourmous. Great news on so many levels. Confirmed PFS = confirmation it works from the company?

The cash balance is a great detail to shut the near term fund raise talk down. £27m as at 31/5. Down 14m from 31/12, but £7.4m spent on the acquisition. So cash burn for first 5 months was c£1m per month?

No rush to raise at all for a long time based o[n this cash burn.

Do you think AGMs normally work differently? Would BP take any question from the floor? If they did they’d be swamped by climate activists buying 1 share to disrupt. The company has been poor in the past in its comms, but recently has been really trying to be as open and communicative as possible I think.

We have 2 weeks waiting for AGM and are also waiting for DE. Waiting periods like this make investors nervous and do also seem to coincide with a lot of ‘what happened to the LFT’ ‘there will be a find raise soon’ ‘it’s all been delayed’ posters suddenly arriving. Coincidence?

Lots of the usual nonsense on here today. Personal favourite is we are not mushrooms. Are we being kept in the dark by a company that has issued 4 RNS this month (its the 15th) and has a whole day for investors to hear it’s plans as well. Not bad volume of comms for June!! I get some frustration - back in 2020 lots of us thought wed get quite rich quite quick. Looks more like very rich a bit more slowly. Still if it’s 18 months for me thats still a 5 year investment which in equity terms is quick ish. Bought more today. This price is pretty odd if you ask me, but hey a few more can’t be a bad thing.

Wyn, give it up! There is a huge fundamental difference between LD and ABDX. aging just checked ABDX has an MCAp of 10m and a year high of nearly double that. So BO feels like a 15-20m price tag. They all ways lose money and in 2022 there turnover fell 70%+. So buying it would burn half current capital day 1 and accelerate the cash burn rate meaning Avacta suddenly needs cash /fund raise overnight. It is literally the stupidest suggestion I ever read.

Wyn, are you serious? With cash availability being the main ‘concern’ around avacta you have been talking abut for months you are suggesting they may be planning spend money (with a premium on current ABDX market cap at least half the cash they have) on a business whose main operation is manufacturing to shut the manufacturing down? I have a better idea for dealing with a business you don't want - not buying it at all!!!! Your other suggestion is they may need it in 5 years - but your other constant bleat is that what the market needs is more info about how they make money soon. The presentation is so clear. They go out of their way to identify the one element they don’t want - manufacturing. No idea what the objective of this nonsense is, but it’s the most confused illogical idea I’ve read in a long time.

Wyn, you are just like Neut. Moan about lack of clarity, then when you have it (they don't want a manufacturer) want to totally ignore it. Abingdon can call themselves whatever they want, but they are a manufacturer. They have a great big factory where they make stuff. I find a lot of what you post strange, but this one is bizarre even by the bar you’ve set.

Neut’s posting history is bizarre. Today he has suggested avacta wont be fully funded if they bought ABDX, but also that it’s very clear on the slides there is no intent to buy manufacturing capacity. That they are ‘fully funded - that’s what the company said’ but has spent all day saying its not clear if they are funded are not. Ive seen suggestions that posters have various names on here, but this is so contrary it is like two people share a log in.